How are you taking part in this consultation?

You will not be able to change how you comment later.

You must be signed in to answer questions

  • Question on Document

    Proposed new recommendations 1.3.1 to 1.3.4 post-anaphylaxis observation periods for children and adults. Do you agree with the proposal to update CG134 recommendations about post-anaphylaxis observation periods with the Resuscitation Council UK’s recommendations? Yes/no. Please provide a rationale for your decision

  • Question on Document

    Proposed new recommendation 1.4.1 admission of children who cannot be safely discharged. This recommendation has been added to make it clear how children who do not meet criteria in proposed recommendations 1.3.1 to 1.3.4 should be cared for. Do you agree with the proposal to recommend that children younger than 16 years who cannot be discharged using the discharge criteria recommended by new proposed recommendations 1.3.1 to 1.3.4 should be admitted under the care of a paediatric medical team? Yes/no. Please provide a rationale for your decision

  • Question on Document

    Proposed new recommendation 1.4.3 offer of adrenaline auto-injectors following emergency treatment for suspected anaphylaxis and when they should be offered. This recommendation has been updated to reflect advice from the MHRA on adrenaline autoinjectors and to align with British Society for Allergy and Clinical Immunology and Resuscitation Council UK guidance about when they should be offered. Do you agree that people should be offered 2 adrenaline auto-injectors as an interim measure before they attend for a specialist allergy appointment, unless the suspected anaphylaxis was due to a drug allergy that can be easily avoided. Yes/no. Please provide a rationale for your decision

  • Question on Document

    Amended recommendation 1.5.1 discharge practice. This recommendation has been amended for consistency with proposed recommendations 1.3.1 to 1.3.4, including the addition of a new bullet which clarifies discharge recommendations for people who have experienced suspected anaphylaxis due to a drug allergy where the drug is subsequently easily avoided. Do you agree with the amended bulleted recommendation? Yes/No. Please provide a rationale for your decision.

  • Question on Document

    Are there any health inequalities issues related to the draft recommendations that you think need to be considered?

Anaphylaxis: assessment and referral after emergency treatment: Draft for consultation

Open for comments Open until   Request commenting lead permission

We have updated this service so that members of the same organisation can now collaborate on a joint online response.

Read our blog to learn more.

Finding more information and committee details

To find NICE guidance on related topics, including guidance in development, see the NICE topic page on allergies.

For full details of the evidence and the guideline committee's discussions, see the full version of the guideline. You can also find information about how the guideline was developed, including details of the committee.

NICE has produced tools and resources to help you put this guideline into practice. For general help and advice on putting our guidelines into practice, see resources to help you put NICE guidance into practice.